Barclays Forecasts Strong Price Appreciation for Evolus (NASDAQ:EOLS) Stock

Evolus (NASDAQ:EOLS) had its price objective hoisted by equities research analysts at Barclays from $22.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 85.19% from the company’s previous close.

Several other analysts have also commented on EOLS. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Evolus in a research report on Tuesday, January 21st. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Friday, February 14th.

Evolus Trading Down 4.7 %

Shares of Evolus stock opened at $13.50 on Wednesday. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $854.83 million, a PE ratio of -14.84 and a beta of 1.33. The company has a 50-day moving average of $12.85 and a two-hundred day moving average of $14.08.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently made changes to their positions in EOLS. KBC Group NV purchased a new position in shares of Evolus in the 4th quarter valued at $49,000. IFP Advisors Inc raised its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after acquiring an additional 4,709 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Evolus in the 3rd quarter valued at $132,000. KLP Kapitalforvaltning AS purchased a new position in shares of Evolus in the 4th quarter valued at $106,000. Finally, Rafferty Asset Management LLC purchased a new position in shares of Evolus in the 4th quarter valued at $115,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.